Recent News

• 04.24.2025 - ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
• 04.24.2025 - ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
• 04.08.2025 - ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
• 04.08.2025 - ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
• 03.27.2025 - ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
• 03.27.2025 - ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
• 03.18.2025 - ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
• 03.18.2025 - ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
• 03.12.2025 - ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
• 03.12.2025 - ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

Recent Filings

• 04.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.17.2025 - DEF 14A Other definitive proxy statements
• 04.17.2025 - ARS Annual Report to Security Holders
• 04.09.2025 - EFFECT Notice of Effectiveness
• 04.07.2025 - 8-K Current report
• 04.07.2025 - PRE 14A Other preliminary proxy statements
• 04.04.2025 - S-3 Registration statement under Securities Act of 1933
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.07.2025 - 8-K Current report